Cooper Companies (NASDAQ:COO) Director Purchases $165,000.00 in Stock

The Cooper Companies, Inc. (NASDAQ:COO) Director Lawrence Erik Kurzius purchased 2,000 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were purchased at an average price of $82.50 per share, for a total transaction of $165,000.00. Following the purchase, the director owned 7,777 shares in the company, valued at approximately $641,602.50. The trade was a 34.62% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Lawrence Erik Kurzius also recently made the following trade(s):

• On Monday, September 29th, Lawrence Erik Kurzius acquired 2,000 shares of Cooper Companies stock. The stock was purchased at an average cost of $68.39 per share, for a total transaction of $136,780.00.

Cooper Companies Stock Performance

Shares of Cooper Companies stock traded up $1.44 on Wednesday, reaching $82.48. 3,618,606 shares of the stock were exchanged, compared to its average volume of 2,470,440. The company has a quick ratio of 1.13, a current ratio of 1.89 and a debt-to-equity ratio of 0.30. The Cooper Companies, Inc. has a twelve month low of $61.78 and a twelve month high of $100.24. The firm has a market capitalization of $16.16 billion, a price-to-earnings ratio of 43.87, a PEG ratio of 2.33 and a beta of 1.05. The business has a 50 day moving average price of $73.91 and a two-hundred day moving average price of $71.74.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.11 by $0.04. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. The company had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the prior year, the company earned $1.04 EPS. Cooper Companies’s quarterly revenue was up 4.6% on a year-over-year basis. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. Analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies declared that its Board of Directors has initiated a stock buyback program on Wednesday, September 17th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical device company to reacquire up to 15.4% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $100.00 price target (up from $94.00) on shares of Cooper Companies in a report on Friday, December 5th. Weiss Ratings reissued a “sell (d+)” rating on shares of Cooper Companies in a report on Monday. Stifel Nicolaus set a $95.00 target price on Cooper Companies and gave the stock a “buy” rating in a report on Friday, December 5th. Wells Fargo & Company lifted their price target on Cooper Companies from $72.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, December 5th. Finally, Barclays reissued an “overweight” rating and set a $91.00 price target on shares of Cooper Companies in a report on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $90.15.

Hedge Funds Weigh In On Cooper Companies

Large investors have recently added to or reduced their stakes in the stock. Horizon Investments LLC grew its position in shares of Cooper Companies by 5.0% in the first quarter. Horizon Investments LLC now owns 2,859 shares of the medical device company’s stock valued at $241,000 after purchasing an additional 136 shares during the period. Wealth Alliance LLC boosted its holdings in Cooper Companies by 4.2% in the 2nd quarter. Wealth Alliance LLC now owns 4,230 shares of the medical device company’s stock worth $301,000 after buying an additional 171 shares during the last quarter. Mesirow Financial Investment Management Inc. increased its stake in Cooper Companies by 1.3% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 14,017 shares of the medical device company’s stock worth $961,000 after buying an additional 175 shares in the last quarter. Pacer Advisors Inc. raised its holdings in shares of Cooper Companies by 0.8% during the third quarter. Pacer Advisors Inc. now owns 23,079 shares of the medical device company’s stock valued at $1,582,000 after acquiring an additional 182 shares during the last quarter. Finally, Citizens Financial Group Inc. RI lifted its position in shares of Cooper Companies by 2.7% in the third quarter. Citizens Financial Group Inc. RI now owns 7,181 shares of the medical device company’s stock valued at $492,000 after acquiring an additional 192 shares in the last quarter. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.